/ Reminders about medications

There are some types of prescription medications you may not be able to take during the trial. Your trial doctor may have you stop taking certain medications. Contact your medical team if you have questions.

Make sure to let the rest of your medical team (outside of the trial) know you are participating in a "pragmatic trial." If your doctor has any questions or needs to prescribe any new medication, have them contact the trial doctor.

/ During each of your follow-up visits, let the trial team know about any changes to your medications, including:

- ☑ New prescription medications
- ☑ Changes to medications (dose changes and stopping)
- ☑ New over-the-counter medications or supplements

/ What are my responsibilities?

As a participant in the CHANGE AFib trial, you will be expected to:

- Participate in scheduled trial visits
- If prescribed dronedarone, take the medication as instructed
- Provide trial team with updates on any medication changes
- Use contraception
- Contact the study team with changes to your contact information

/ Whom can I contact with questions or concerns?

If you have any questions or concerns, call your trial doctor or another member of the trial staff.

v.12.13.22

CHANGE AFib

Newly diagnosed atrial fibrillation can be overwhelming.

Learn about the CHANGE AFib trial that may help patients with newly detected AFib.

About the CHANGE AFib Trial

CHANGE AFib is studying whether early treatment with the drug dronedarone improves cardiovascular and long-term outcomes in patients presenting to the hospital with first-detected atrial fibrillation (AFib).

Dronedarone is an FDA-approved rhythm control (antiarrhythmic) drug that helps control an irregular heartbeat. This is a US-based study specifically for:

- People who present to the hospital or outpatient clinic
- Are age 21 or older
- Have newly detected AFib (diagnosed within the past 120 days)

The trial includes three visits (one enrollment visit and two follow-up visits).

/ Learn more information at CHANGEAFIB.org

Screening period

The screening period occurs while you are at the hospital or an outpatient clinic visit for newly detected AFib. During this period, the trial team will:

- Determine if you are eligible to participate
- Explain what is required of you in this trial
- Answer your questions

Trial treatment period

/ Enrollment visit:

Occurs while you are at the hospital with newly detected AFib or in an outpatient visit within 120 days of your diagnosis of first-detected AFib. During this visit, you or a legally authorized representative will:

- Sign a consent form to participate
- Be randomly assigned to either the trial intervention (dronedarone taken orally) or usual care
- Find out which treatment you are receiving
- Answer questions about your health, well-being, and quality of life

/ First follow-up visit:

Occurs 3 to 9 months after your enrollment visit. During this in-person or virtual visit, you will:

- Review your medical records with trial staff
- Answer questions about recent medical care:
  - Doctor visits and lab tests
  - Current medications
  - Recent hospitalizations

/ Final follow-up visit:

Occurs 12 months after your enrollment visit. During this in-person or virtual visit, you will:

- Review the same information as the first follow-up visit
- Answer questions about your health, well-being, and quality of life